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Inflammatory arthritis (e.g. rheumatoid arthritis; RA) is a complex disease driven by the 
interplay of multiple cellular lineages. Fullerene derivatives have previously been shown to have 
anti-inflammatory capabilities mediated, in part, by their ability to prevent inflammatory 
mediator release by mast cells (MC). Recognizing that MC can serve as a cellular link between 
autoantibodies, soluble mediators, and other effector populations in inflammatory arthritis, it was 
hypothesized that fullerene derivatives might be used to target this inflammatory disease. A 
panel of fullerene derivatives was tested for their ability to affect the function of human skin-
derived MC as well as other lineages implicated in arthritis, synovial fibroblasts and osteoclasts. 
It is shown that certain fullerene derivatives blocked FcγR- and TNF-α-induced mediator release 
from MC; TNF-α-induced mediator release from RA synovial fibroblasts; and maturation of 
human osteoclasts. MC inhibition by fullerene derivatives was mediated through the reduction of 
mitochondrial membrane potential and FcγR-mediated increases in cellular reactive oxygen 
species and NF-κB activation. Based on these in vitro data, two fullerene derivatives (ALM and 
TGA) were selected for in vivo studies using K/BxN serum transfer arthritis in C57BL/6 mice 
and collagen-induced arthritis (CIA) in DBA/1 mice. Dye-conjugated fullerenes confirmed 
localization to affected joints in arthritic animals but not in healthy controls. In the K/BxN 
moldel, fullerenes attenuated arthritis, an effect accompanied by reduced histologic 
inflammation, cartilage/bone erosion, and serum levels of TNF-α. Fullerenes remained capable 
of attenuating K/BxN arthritis in mast cell-deficient mice Cre-Master mice, suggesting that 
lineages beyond the MC represent relevant targets in this system. These studies suggest that 
fullerene derivatives may hold promise both as an assessment tool and as anti-inflammatory 
therapy of arthritis. 
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Abstract
Inflammatory arthritis (e.g. rheumatoid arthritis; RA) is a complex disease driven by the in-
terplay of multiple cellular lineages. Fullerene derivatives have previously been shown to
have anti-inflammatory capabilities mediated, in part, by their ability to prevent inflammatory
mediator release by mast cells (MC). Recognizing that MC can serve as a cellular link be-
tween autoantibodies, soluble mediators, and other effector populations in inflammatory ar-
thritis, it was hypothesized that fullerene derivatives might be used to target this
inflammatory disease. A panel of fullerene derivatives was tested for their ability to affect
the function of human skin-derived MC as well as other lineages implicated in arthritis, syno-
vial fibroblasts and osteoclasts. It is shown that certain fullerene derivatives blocked FcγR-
and TNF-α-induced mediator release from MC; TNF-α-induced mediator release from RA
synovial fibroblasts; and maturation of human osteoclasts. MC inhibition by fullerene deriva-
tives was mediated through the reduction of mitochondrial membrane potential and FcγR-
mediated increases in cellular reactive oxygen species and NF-κB activation. Based on
these in vitro data, two fullerene derivatives (ALM and TGA) were selected for in vivo stud-
ies using K/BxN serum transfer arthritis in C57BL/6 mice and collagen-induced arthritis
(CIA) in DBA/1 mice. Dye-conjugated fullerenes confirmed localization to affected joints in
arthritic animals but not in healthy controls. In the K/BxN moldel, fullerenes attenuated ar-
thritis, an effect accompanied by reduced histologic inflammation, cartilage/bone erosion,
and serum levels of TNF-α. Fullerenes remained capable of attenuating K/BxN arthritis in
mast cell-deficient mice Cre-Master mice, suggesting that lineages beyond the MC repre-
sent relevant targets in this system. These studies suggest that fullerene derivatives may
hold promise both as an assessment tool and as anti-inflammatory therapy of arthritis.
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Introduction
Oxygen metabolism has an important role in the pathogenesis of inflammatory arthritis and
therefore therapies that target its dysregulation have been investigated as potential treatments.
Reactive oxygen species produced in the course of cellular oxidative phosphorylation, and by
activated phagocytic cells during oxidative bursts, exceed the physiological buffering capacity
and result in oxidative stress [1,2]. Various forms of antioxidant therapy have demonstrated
promising results in experimental arthritis models [3–7]. The polyphenolic fraction of green tea
containing potent antioxidants ameliorates collagen-induced arthritis [8]. A traditional Medi-
terranean diet relatively high in antioxidants improved RA disease activity and functional status
after three months compared with a standard 'Western' diet [9]. In a separate study of patients
with RA, antioxidant supplementation with vitamin A, E, and C increased plasma antioxidant
levels with a corresponding decrease in malondialdehyde, a marker of oxidative stress; however,
a clinical response was not reported [10]. Carvedilol, an adrenergic antagonist with antioxidant/
anti-inflammatory properties effectively suppressed inflammation in two arthritis models [3].
The cellular interplay leading to inflammatory arthritis is complex. In many patients with
rheumatoid arthritis (RA), the synovium exhibits an increase in the number of mast cells (MC),
in some cases representing 5% or more of the expanded population of total synovial cells [11,12].
MC accumulation differs substantially from patient to patient, in general varying directly with
the intensity of joint inflammation [13]. Accompanying the increased numbers of MC, their me-
diators are also present at higher concentrations in the synovial fluid of inflamed human joints.
These mediators include histamine, tryptase, and TNF-α, all readily elicited fromMC upon expo-
sure to various immunological and non-immunological stimuli [14–16]. Synovial fibroblasts also
contribute to inflammatory arthritis, both by amplifying inflammation and by contributing to tis-
sue injury in the form of invasive pannus [17,18]. Lastly, osteoclasts are cells of the monocyte/
macrophage lineage that are directly responsible for the bone destruction in inflammatory arthri-
tis; therapies that reduce osteoclast function are being investigated as ways to reduce bone erosion
in inflammatory arthritis [19]. Reactive oxygen species (ROS) act as intracellular signaling mole-
cules in the regulation of RANKL-dependent osteoclast differentiation involving NF-κB [20–23].
Fullerenes or “Buckyballs” are one class of nanomaterials that represent the third allotrope
(structural arrangement) of carbon. Previous studies have demonstrated that fullerene deriva-
tives can stabilize human MC depending on the structure of the chemical moieties added to the
carbon cage [24,25]. Given that fullerene derivatives have general anti-inflammatory properties
through reductions in ROS levels and the blunting of the NF-κB signaling pathway [24,26–28]
it was hypothesized fullerene derivatives could ameliorate inflammatory arthritis. To test this
hypothesis, a panel of water-soluble fullerene derivatives were developed and tested in vitro for
their ability to alter mediator release from arthritis-related cells including MC and synovial fi-
broblasts, as well as their effect on human osteoclast formation. The best candidates were se-
lected for their ability to attenuate inflammatory arthritis in vivo using the K/BxN serum
transfer arthritis and CIA [29,30]. It is demonstrated that the ability of fullerene derivatives to
inhibit inflammatory cell mediator release was dependent on the moieties added to the carbon
cage. The ability to inhibit in vitromediator release translated to in vivo efficacy only in the K/
BxN induced mice, but this effect was independent of the presence of MC. CIA mice showed
no reduction in disease onset or progression when treated with fullerene derivatives. Of partic-
ular interest, dye-conjugated fullerene derivatives localized specifically to inflamed joints, and
did not accumulate in other organs. Our results suggest rationally designed fullerene deriva-
tives may provide an effective therapeutic option for the treatment of inflammatory arthritis by
targeting ROS to prevent stimulation of pro-inflammatory cytokines, osteoclast formation, and
stabilizing critical cells involved in RA progression.
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Methods and Materials
Fullerene derivatives
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was ap-
proved by the International Animal Care and Use Committee of the University of North Caro-
lina at Greensboro (Protocol Number: 11–02). All techniques were performed under isoflurane
anesthesia, and all efforts were made to minimize suffering.
A panel of fullerene derivatives was synthesized at Luna Innovations and characterized for
particle size using dynamic light scattering (Malvern Instruments, Zetasizer Nano ZS, Westbor-
ough, Massachusetts, USA), qNano (Izon Science, qNano, Cambridge, Massachusetts, USA)
and nano particle tracking analysis, (Malvern Instruments, Nanosight LM10, Westborough,
Massachusetts, USA), zeta potential (Malvern Instruments, Zetasizer Nano ZSP, Westborough,
Massachusetts, USA), NMR (Agilent Technologies, 400 Mhz NMR Spectrometer, Santa Clara,
California, USA), and FT-IR (Agilent Technologies, Varian 670 FT-IR, Santa Clara, California,
USA). A representative physiochemical characterization schematic for the two fullerene deriva-
tives used for the in vivo studies (ALM, a liposome encapsulated C70 fullerene and TGA, a
water-soluble C70 fullerene conjugated with four glycolic acids) is shown in [27,31].
Inflammatory mediator release from bone marrow-derived MC (BMMC)
and human MC
The activation of MC through Fcγ receptors is one constituent that drives inflammatory arthri-
tis. Unlike primary human MC, mouse MC express FcγRIII and may be stimulated to release
mediators via this receptor in culture, although activation is constrained by the inhibitory re-
ceptor FcγRII [32]. Thus, BMMC were generated from FcγRII-deficient mice by incubation for
at least 4 weeks in SCF (12.5 ng/ml) and IL-3 (10 ng/ml)-containing medium [29]. Cells were
incubated with or without fullerene derivatives overnight [10 μg/ml; [25]], washed and rat
anti-FcγRII/III (2.4G2, 1μg/ml) added for two hours. Immune complex (IC) stimulation was
mimicked by the addition of donkey anti-rat (DAR; 1 μg/ml) for 30 minutes (degranulation) or
24 hours (cytokine) and cellular lysates prepared [33] collected and IL-1βmeasured using
ELISA as described [25]. Human connective tissue MCTC [34] were generated from skin and
stimulated with immune complexes (IC) and mediator release measured as described [35]. Ini-
tial experiments determined optimal concentrations of IC for human MCmediator release was
8.8 μg/ml antibody with 0.13 μg/ml NP-BSA (not shown).
Synovial fibroblast cytokine production
Human fibroblasts (PC37303A1-S-Passage 1) from the synovium of RA patients (n = 5) hav-
ing joint replacement surgery (Asterand, Detroit, Michigan, USA) were plated in triplicate on
a 96 well plate using RPMI complete medium. Cells were incubated overnight with or with-
out fullerene derivatives at various concentrations, washed, and activated with or without
10 ng/ml of TNF-α for 12 hours. The supernatants (in triplicate) were assayed for IL-6 and
IL-8 using ELISA [36].
Osteoclast differentiation
Human osteoclasts were obtained from peripheral blood mononuclear cells (PBMC) as de-
scribed previously [37]. Mononuclear cells were cultured in complete DMEM containing
RANKL (25 ng/ml) and M-CSF (25 ng/ml). Fullerene derivatives were added at varying con-
centrations and remained in the medium until the end of the experiment (eight days). Cells
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were washed, cytocentrifuge preparations made, and analyzed for tartrate resistant acid phos-
phatase (TRAP) activity by cytochemistry (Sigma Aldrich, Acid Phosphatase Leukocyte assay,
St. Louis, Missouri, USA). At eight days multinucleated cells containing three or more nuclei
were counted. TRAP-positive cells containing three or more nuclei were considered to be dif-
ferentiated osteoclasts. Experiments were done in triplicate, 25 microscopy fields at 40× magni-
fication were evaluated for each sample. Quantitation of osteoclasts TRAP staining was
performed using the infrared imaging analysis (Li-Cor Biosciences, Odyssey Imaging CLx Sys-
tem, Lincoln, Nebraska, USA).
Measuring NF-κB levels using in-cell Western
Human MC were plated in triplicate in 96-well plates and incubated as above with fullerene de-
rivatives, washed, and activated with or without FcγR stimulation for 24 hours as above. After
treatment, cells were fixed by adding formalin to a final concentration of 3.7% formaldehyde
and incubated at room temperature for 10 minutes. After fixation, the plates were washed with
PBS then permeabilized (PBS containing 0.1% Triton-X-100) by washing three times for 10
minutes on a bench top shaker and finally rinsed once with PBS containing 0.1% Tween 20.
Cells were blocked using 50 μL/well blocking buffer (Li-Cor Biosciences, Odyssey Blocking
Buffer, Lincoln, Nebraska, USA) for one hour at room temperature. Primary antibodies, β-
Actin (1:1000) (Cell Signaling Technology, Danvers, Massachusetts, USA) and NF-κB (1:500)
(Cell Signaling Technology, Danvers, Massachusetts, USA), incubated overnight at 4°C using
20 μL/well, washed three times with 100 μL/well PBS-Tween, and centrifuged at room temper-
ature. Secondary antibodies were prepared as for Western blotting with a few modifications:
IRDye 680CW and 800 CW conjugates of goat-anti-mouse-IgG (Li-Cor Biosciences, Lincoln,
Nebraska, USA) were used at 1:1000 dilution for detection of antibody targets in the 800 and
700 nm channels (green and red respectively). Plates were incubated with 20 μL/well secondary
antibody solutions for 1.5 hours at room temperature in the dark, washed three times for 10
minutes with PBS-Tween at room temperature, and filled with 50 μL/well of PBS to reduce sur-
face disturbances when scanning. The 800-channel antibody signals were normalized to the
700-channel signals derived from IR-680 conjugated secondary. Background control wells
were prepared by omitting primary antibodies, IRDye 680CW and IRDye 800CW (ie second-
ary only, Li-Cor Biosciences, Lincoln, Nebraska, USA). Plates were scanned and analyzed using
an Odyssey IR CLx system using the Odyssey imaging software 3.0 (Li-Cor Biosciences). Scan
settings were high image quality, 169 μm resolution, intensity 6.0 for the 700-channel, and 6.0
for the 800-channel with an offset of 4.0 mm. For signal quantification, antibody signals were
analyzed as the average 800-channel integrated intensities from duplicate wells normalized to
the 700-channel signal integrated intensity to correct for well-to-well variations in cell number.
Results are expressed as percent inhibition of the NF-κB responses (means ± standard errors of
the mean) compared to vehicle-treated controls.
Mitochondrial membrane potential
Active mitochondria with high membrane potential (ΔCm) accumulate the lipophilic cationic
probe 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1) in aggre-
gates, which are red, whereas, in the mitochondria with low ΔCm (inactive), JC-1 stays in a mo-
nomeric, green form [38,39]. This renders the red:green ratio, a sensitive indicator of the
mitochondrial ΔCm changes, and indicates cellular ROS production. The change in the mito-
chondrial membrane potential was measured in fullerene derivative-treated human MC using
JC-1 as previously described [40]. Cells (5x105/500 μl) were incubated overnight with fullerene
derivative as above, washed, loaded with 2 μM JC-1 for 15 minutes, and activated as above.
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After cell stimulation, the green fluorescence (the monomeric JC-1) and red fluorescence (JC-1
aggregates) were measured using the FL-1 and FL-2 channels, respectively, with flow cytometry
(Becton Dickinson, FACSCalibur, East Rutherford, New Jersey, USA).
Reactive oxygen species measurements
Mast cells were incubated overnight with fullerene derivatives, washed, and incubated for 30
minutes with 2',7'-dichlorodihydrofluorescein diacetate (DCF-DA, final concentration of
5 μM). Next, cells were washed and resuspended in fresh media, placed in a cuvette and activat-
ed with IC as above for 50–100 seconds. ROS fluorescence intensity was measured at 523 nm
wavelength over a 12 minute time interval using spectrophotometry (Perkin Elmer, LS55 Lu-
minescent Spectrometer, Waltham, Massachusetts, USA). All samples were measured in dupli-
cate and performed at least three times.
Odyssey imaging of fullerene derivatives in vivo
To track the fate of fullerene derivatives in vivo an IRDye 800CW conjugated to a C70 fullerene
using a protocol as described [41]. These dyes are used in conjunction with the Xenogen imag-
ing system and have been widely used for bio-distribution studies [42]. The success of the con-
jugation and removal of free dye was verified using MALDI-MS (Bruker Corporation, Billerica,
Massachusetts, USA) and absorption spectra. Live mice with or without full-blown disease (K/
BxN; day 14) were injected with various concentrations of the fullerene-dye conjugate and
whole body images obtained over 24 hours.
Inflammatory arthritis
K/BxN serum (125 μl) was injected intraperitoneally (i.p.) on experimental days 0 and 1. Ful-
lerene derivatives (40 μg/100 μl PBS) were injected i.p into C57BL/6 or mast cell-deficient Cre-
master mice one day before the first serum injection and then every other day. Clinical scoring
is detailed below. Ankle swelling i were measured using calipers along with the clinical indices
as described [29]. In some experiments, serum was collected at day 14 and assayed for TNF-α
levels by ELISA (R&D systems, Minneapolis, Minnesota, USA). Mice were sacrificed, ankle sec-
tions removed, and sections scored as described below. Animal studies for the Cre-Master mice
were approved by the Dana Farber Cancer Institute.
To examine fullerene derivatives in the collagen-induced arthritis (CIA) model [30,43]
DBA/1 mice, bovine type II Collagen (CII; MD Bioproducts, St Paul, Minnesota, USA) was dis-
solved in 10 mM acetic acid at a 4 mg/ml by stirring overnight at 4°C, added to an equal vol-
ume of complete Freund’s adjuvant (Sigma Aldrich, St Louis, Missouri, USA), and
homogenized as described [44]. To induce CIA, 8-week-old female DBA/1 inbred mice (Harlan
Laboratories, Dublin, Virginia, USA) were injected intradermally at the tail base with 100 μl
CII in CFA. Fullerenes (40 μg/100 μl) or PBS were injected i.p. before disease induction and
every other day after the first collagen injection. The animals received another injection of CII
in CFA at the right hind paw two weeks after the primary immunization. Ankle and paw swell-
ing was measured along with the clinical indices every other day. After four weeks, mice were
sacrificed, serum collected, and histochemistry performed on ankles using H&E staining (IHC
World, Woodstock, Maryland, USA). All animal studies for the CIA model were approved by
University of North Carolina at Greensboro institutional review board.
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Disease analysis
Several parameters of disease were analyzed to determine efficacy of treatment [29,45]. The
clinical index for each paw/ankle was measured, blinded to treatment group, as follows: 0 = no
evidence of inflammation; 1 = subtle inflammation (metatarsal phalanges joints, individual
phalanx, or localized edema); 2 = easily identified swelling but localized to either dorsal or ven-
tral surface of paw/ankle; and 3 = swelling on all aspects of paw/ankle. Maximum score = 12.
Quantitative arthritic scores of each mouse (paws and ankles) were measured and expressed as
the sum of the measured scores of four limbs. Here, actual swelling of the joint is measured
using calipers. The degree of swelling in normal hind limbs and front limbs is measured every
other day starting one day before injections, averaged, and compared statistically to fullerene
derivatives treated animals. Histology (hematoxylin and eosin) of paw/ankle sections were ana-
lyzed for synovial hyperplasia, pannus formation, and inflammatory cellular infiltrate. Cyto-
kine measurements (TNF-α, IL-1) were measured as described [36] using sera from treated
and untreated mice.
Statistics
Data are presented as mean ± standard deviation. Analysis of variance (ANOVA) with New-
man–Keuls post hoc test was used to compare the effects of fullerene derivatives on mediator
release fromMC and on inflammation in murine models, with the significance for all tests set
at P< 0.05.
Results
The efficacy of fullerene derivative inhibition on inflammatory mediator
release and osteoclast formation depends on functional moieties added
to the carbon cage
A panel of 40 fullerene derivatives was tested for the ability to inhibit Fcγ receptor-dependent
degranulation and cytokine production from human and mouse MC. Previous studies demon-
strated an overnight incubation with 10 μg/ml was optimal for MC stabilization to FcεRI-de-
pendent [25] and-independent [46] stimulation and was thus used for these studies.
Approximately 15% of the fullerene derivatives tested significantly (p<0.05) inhibited both de-
granulation and IL-1β (Fig 1A–1C). As demonstrated previously examining FcεRI-dependent
mediator release [25], several fullerene derivatives exhibited inhibitory capabilities on both de-
granulation and cytokine production in Fcγ-stimulated BMMC (Fig 1A) and IC-stimulated
human tissue-derived MC (Fig 1B) which was dependent on the side chain moieties added to
the carbon cage. Cytokine release from TNF-α-challenged synovial fibroblasts was significantly
inhibited by 25% for all fullerene derivatives tested (Fig 1C). The two most efficacious cytokine
blockers (ALM and TGA) also inhibited the formation of bone resorbing osteoclasts (Fig 1D).
Thus, fullerene derivatives inhibit critical parameters important for the pathologies associated
with inflammatory arthritis as assessed by in vitromodels.
Fullerene derivatives inhibit mitochondrial membrane potential, ROS
production, and NF-κB activation
Unstable mitochondrial membrane potential regulates ROS production [47]. Our previous
work strongly suggested that fullerene derivatives inhibited degranulation through a pathway
involving mitochondrial signaling proteins [24] and ALM is specifically designed to target mi-
tochondrial membranes [27]. However, no studies have examined the role of mitochondrial
membrane potential or fullerene derivatives in IC mediator release from human MC. Given
Fullerenes Inhibit Inflammatory Arthritis
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Fig 1. Fullerene derivatives reduce degranulation and cytokine production from synovial fibroblast
from RA patients, mouse BMMC, and humanMC (hMC), and osteoclast formation from human PBMC.
Fig 1A shows FcγRII-null BMMC incubated with fullerene derivatives overnight (10 μg/ml). The next day anti-
FcγRII/III antibody 2.4G2 or isotype control was added followed by cross-linking donkey anti-rat (DAR) F
(ab)2. Cells were centrifuged and β-hexosaminidase release or IL-1 production determined in supernatants or
lysates, respectively. Data shown are means ± SE of triplicate samples that is representative of three
experiments. All data was statistically significant with P values < 0.05. In Fig 1B tissue MC were incubated
with fullerene derivatives (10 μg/ml) overnight, washed and preformed IgG anti-NP–NP-BSA immune
Fullerenes Inhibit Inflammatory Arthritis
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that increases in MC mitochondrial membrane potential closely paralleled degranulation and
previous studies suggested mitochondrial signaling pathways were affected by fullerene deriva-
tives, it was hypothesized that the inhibitory effect of fullerene derivatives on MC degranula-
tion may involve modulation of the mitochondrial membrane potential response. Initial
studies demonstrated that MC mitochondrial membrane potential was dependent on dose (Fig
2A) and time (Fig 2B) of the degranulation stimulus using IC. As seen in Fig 2C, MC incubated
with fullerene derivatives prior to challenge with optimal concentrations of IC demonstrated a
decrease in mitochondrial membrane potential compared to untreated MC. ALM and TGA
also inhibited IC-induced increases in ROS activity (Fig 2D). Lastly, NF-κB, which regulates
genes controlling the amount of ROS and TNF-α in the cell [48,49], was down-regulated in IC-
treated MC pre-incubated with fullerene derivatives (Fig 2E). Thus, decreased MC cellular acti-
vation through IC is due in part to decreased mitochondrial membrane potential, ROS produc-
tion, and NF-κB activation. Two of the overall best inhibitors of these parameters included
ALM and TGA, which were chosen for further study.
Fullerene derivatives can target the inflamed synovial joints, but not
organs, in vivo
In order to determine the bio-distribution of fullerene derivatives, in vivo experiments were per-
formed using C70-conjugated to an IR-800 dye. As seen in Fig 3, at seven days after serum (Fig
3A) or vehicle (Fig 3B) injection, during the peak symptom scores, the fullerene dye conjugate
is clearly visible six hours post injection in the joints of mice with inflammatory arthritis. In
contrast, control mice without inflammatory arthritis receiving the same dose of fullerene-dye
conjugates did not demonstrate fullerene-dye accumulation in the joints. These data confirm
that specifically derivatived fullerenes are capable of migrating and accumulating within the
joints of mice with “active” inflammatory arthritis where they are poised to inhibit the inflam-
matory cascade. Furthermore, organ evaluation (Fig 3C) revealed ratios reveal that very little
fullerene derivative accumulated non-specifically throughout the body, as quantified in Fig 3D.
ALM and TGA prevent inflammatory arthritis
Given our results demonstrating the ability of fullerene derivatives to inhibit MC-mediated dis-
eases [24,25,46] as well as general [28] inflammation, it was hypothesized that fullerene deriva-
tives may reduce the severity of inflammatory arthritis in vivo, in part by inhibiting MC
function. Both ALM and TGA strikingly inhibited K/BxN-induced arthritis in B6 mice (Fig 4A).
Histochemically, the serum-treated mice demonstrated typical synovial hyperplasia, pannus for-
mation, and inflammatory infiltrates (Fig 4B -top). In contrast, TGA treated animals had less
complexes [8.8 μg/ml anti-NP Ab with 0.13 μg/ml NP-BSA [35]], were incubated with MC for 30 minutes or
four hours. Supernatants and cell lysates were prepared for mediator release analysis as described. Data is
expressed as mean ± SE from three individual experiments. P values < 0.05 by ANOVA when experimental
values are compared with the Ab-only control (not shown). Fig 1C shows fullerene derivatives can inhibit
cytokine production from rheumatoid arthritis-derived synovial fibroblasts. Synovial fibroblasts from RA
patients were preincubated with or without various fullerene derivatives (10 μg/ml) overnight, washed, and
incubated with TNF-α (10 ng/ml for 12 hours). Supernatants were saved and cytokines measured in the
supernatants. The percent inhibition of the treated cells was calculated based on the release of cytokines
from non- fullerene derivative treated cells. Fig 1D shows the ability for fullerene derivatives to inhibit
osteoclast formation. Human PBMC were incubated without (negative) or with RANK ligand (30 ng/ml) and
GMCSF (25 ng/ml). After one hour fullerene derivatives were added (10 μg/ml) and remained throughout. In
order to verify the differentiation of mononuclear cells to osteoclasts, after eight days of culture, cells were
analyzed for tartrate resistant acid phosphatase (TRAP) activity by cytochemistry. The cells with the reddish
color represent osteoclast formation and are quantified in the graph (bottom). Results are representative of
two separate experiments. Magnification 40X.
doi:10.1371/journal.pone.0126290.g001
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evidence of clinical joint inflammation (Fig 4B -middle) which was comparable to non-diseased
animals (Fig 4B -bottom). A critical functional role for MC cells in arthritis pathogenesis has
been suggested in K/BxN serum transfer arthritis [29] while more recent studies using a Kit-in-
dependent model for MC-deficiency were fully susceptible to antibody-induced autoimmune ar-
thritis, as Kitmutations affect numerous cell types of both immune and non-immune origin
[50]. To this end, Cre-mediated mast cell eradication (Cre-master) mice are used to obviate the
Fig 2. Mitochondrial membrane potential correlates with MC degranulation through FcγR receptors and is inhibited by fullerene derivatives. In Fig
2A, change in mitochondrial membrane potential as a function of the concentration of IC stimulus was assessed. Human MCs were stimulated with graded
concentrations of preformed IgG anti-NP/NP-BSA immune complexes as indicated for 10 minutes. As a control, cells without JC-1 and cells with JC-1 plus
NP IgG only (no antigen) were incubated in parallel. The above experiment is representative of two separate samples. The percent of degranulation from
these cells was 23%, 32%, 39%, and 45% respectively. Mitochondrial membrane polarization was quantified by cytofluorimetry (FL2 channel) using FACs
analysis as described above. As seen in Fig 2B, change in mitochondrial membrane potential as a function of time with fixed concentration of IC stimulus was
assessed. Human MCs were stimulated with 8.8 μg/ml anti-NP Ab with 0.13 μg/ml NP-BSA of preformed IgG anti-NP/NP-BSA IC for the indicated times. As a
control, cells without JC-1 were incubated in parallel. In Fig 2C, Fullerene derivatives inhibit IC-induced increases in mitochondrial membrane potential. Mast
cells were incubated overnight with ALM or TGA (10 μg/ml) or media only. The next day cells were challenged with media containing JC-1 probe for 10
minutes at 37°C with or without IC (as in A). After 10 minutes cells were washed with cold PBS, centrifuged and the JC-1 aggregates detected using the FL2.
The above experiment is representative of three separate samples. As shown in Fig 2D fullerene derivatives inhibit IC-induced elevations in intracellular ROS
levels. Mast cells were incubated overnight with fullerene derivatives, washed and DCF-DA added to cells for 30 minutes at 37°C. After washing cells were
activated with optimal concentrations of IC and the fluorescence intensity measured at 525nm after establishing baseline. Figs. show representative numbers
from duplicate samples for each condition and are representative of three separate MC cultures. Fig 2E shows that fullerene derivatives can block Fcγ
receptor mediated activation of the MC transcription factor NF-κB. Mast cells were incubated with or without fullerene derivatives (10 μg/ml) overnight,
washed, and challenged with IC for 24 hours. After washing, in-cell Westerns were performed using the manufacturers protocol. Control wells (those without
primary antibodies) were reserved as a source for background well intensity. Further controls were cells incubated without fullerene derivatives or IC. Results
represent results from two separate experiments.
doi:10.1371/journal.pone.0126290.g002
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Fig 3. Fullerenes targets joints in inflammatory arthritis. In Fig 3A, non-arthritic control (left) and arthritic (right) mice were injected intravenously with
50 μg/300μl of IR800 conjugated fullernes and imaged six hours later using the Odyssey imaging system. Control mice (left) without inflammatory arthritis
received the same concentration of fullerene-dye. Note the joint localization of the Dye-fullerene conjugate in the arthritic mouse. Fig 3B shows whole mouse
imaging and Fig 3C shows imaging of externalized organs performed 24 hours after fullerene-dye injection (50 μg/300 μl). Fluorescence intensity is equally
portrayed in all and represent a typical mouse out of three treated in parallel. All of the images have undergone background noise subtraction. Fig 3D shows
the quantification of fullerene dye concentration in representative organs from the mouse portrayed in Fig 3B–3C.
doi:10.1371/journal.pone.0126290.g003
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deleterious effects associated with Kitmutated mice. To test whether this effect was attributable
to MC, we replicated the experiment (TGA fullerene only) in MC-deficient Cre-Master mice. A
detectable fullerene induced effect remained (Fig 4C) in the MC deficient mice. It is important
to note that the untreated K/BxN induced MC-deficient mice were still susceptible to inflamma-
tory arthritis onset, reiterating that the K/BxNmodel is not MC-driven, but the fullerenes could
Fig 4. Fullerene derivatives attenuate inflammatory arthritis in the K/BxN but not CIA model. As shown in Fig 4A, C57Bl/6 (n = 5 mice/group) mice
were injected with K/BxN serum as described in Methods. Two fullerene derivatives, TGA or ALM (40 μg/100 μl), were injected i.p. on Day 0, 2, and every
second day. As a control 100 μl of PBS was injected in the control group. Measurements were taken every second day by a blinded observer. Error bars,
±SEM. The * indicates significant differences observed on that day in fullerene derivatives compared to non-fullerene-treated mice (see text). Fig 4B shows
representative ankle sections from K/BxN treated C57Bl/6 mice without TGA (left) or with TGA (middle). Control mice not serum challenged are shown on the
right. (Scale bars, 50 μm). Fig 4C shows disease pathogenesis in Cre-Master mice (n = 10 mice/group) with and without fullerene derivative, TGA, therapy as
above. Fig 4D. Fullerene derivatives inhibit serum TNF-α levels in the K/BxN model and prevent the joint erosion induced by inflammatory arthritis. Serum
levels were obtained at peak symptoms from K/BxN-induced C57Bl/6 mice and TNF-αmeasured as described (CIA model revealed no significant
reductions) [36] (n = 5 mice per group).
doi:10.1371/journal.pone.0126290.g004
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still ameliorate disease progression despite the absence of MC. These studies suggest that the ef-
fect of the fullerenes tested is mediated by multiple cell lineages.
The CIA model of inflammatory arthritis shares several pathological commonalties with
RA, synovial hyperplasia, mononuclear cell infiltration, cartilage degradation, and plays a
prominent role in joint destruction [43]. Interestingly, recent studies using Mcpt5-iDTR sys-
tem have implicated MC in the maturation of the autoimmune response and therefore arthritis
intensity in these animals[51]. However, unlike in K/BxN arthritis, we observed only a small
and non-significant improvement in fullerene treated animals compared to untreated animals
when measuring ankle thickness and clinical indices (data not shown).
Consistent with these clinical scores, the levels of serum TNF-α were significantly lower at
day 14 in the mice treated with TGA and ALM compared to those mice given vehicle (PBS)
only injection (p = 0.0009 and 0.01, respectively) in the K/BxN model (Fig 4D; Cre-Master
mice not tested), but not in CIA (data not shown).
Toxicological assessment of ALM and TGA
In separate experiments, high concentrations of ALM and TGA were injected under the same
protocol as above except using 100 mg/kg. There was no significant increase in serum activity
of ALT and AST between the untreated and ALM and TGA-treated animals, indicating no
overt liver toxicity. Serum creatinine levels were measured in order to assess kidney toxicity
[52]. These initial results suggest that ALM and TGA are not acutely toxic to the liver or kidney
(data not shown).
Discussion
The molecular events leading to inflammatory arthritis are complex and involve a number of
factors. Some studies have implicated MC in arthritis, and preventing mediator release from
these cells has become a target for therapeutic intervention [11,53]. The initial impetus for
these studies was the observation that certain fullerene derivatives can stabilize MC in vitro
and in vivo. In the present studies, we confirmed that fullerenes could partially limit MC activa-
tion in vitro, an effect associated with specific derivitzation of the nanoparticles. Interestingly,
while these compounds proved moderately effective in immune complex-driven K/BxN serum
transfer arthritis, this effect was not fully attributable to MC inhibition, because the agents re-
tained modest but discernable effect in MC-deficient Cre-Master mice. Consistent with this re-
sult, fullerenes manifested in vitro effects of a potentially anti-inflammatory nature on other
lineages implicated in arthritis: fibroblasts and osteoclasts. However, in the more complex CIA
model, the fullerene effect was no longer discernable, despite recent evidence (in the B6 back-
ground) for a role of MC in this model [51], which may be further explained by the model of
arthritis induction and future experiments will be directed towards such studies, including
using the CIA model in the MC-deficient mice.
The strategy for these studies was to first determine which fullerene derivatives inhibited
human and mouse MC through arthritis–relevant stimulation. In addition, the ability of fuller-
ene derivatives to inhibit synovial fibroblast cytokine production and osteoclast development
were considered important prerequisites for predicting in vivo efficacy, as an amalgam of cell
types govern the degree and severity of arthritis [19,54]. To this end, a panel of fullerene deriva-
tives were tested for their ability to inhibit MC FcγR-mediated responses [55]. A clear struc-
ture-activity relationship between fullerene derivatives and inhibitory function was not
defined. However, in general, the fullerene derivatives that were most efficient at inhibiting
MC mediator release had side chain moieties that induced maximum water solubility, a zeta
potential between 37 and -146 mV, and particle sizes between 50 to 200 nM. Of these, both
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TGA and ALM have been shown previously to inhibit IgE-mediated degranulation and cyto-
kine production [25] and in response to other non-IgE-mediated secretagogues [46]. The TGA
(tetra-glycolic acid) is a C70 series with four carboxyl groups, which confers water solubility. It
is postulated that the mechanism by which TGA exerts its effect via an interaction between the
carboxyl groups and the electrons on the fullerene cage. To examine this point, a similar fuller-
ene derivative that presented a triethylene glycol spacer between the carboxyl groups and the
cage was prepared. TEG-TGA (-25 mV zeta potential; 94 nM particle size) did not block MC
mediator release nor did it interfere with cytokine release (not shown). This result is consistent
with the hypothesis that proximity of the carboxyl groups to the cage is necessary for activity.
The mitochondrial electron transport is the machinery that orchestrates one of the most
fundamental of chemical processes; the generation of cellular energy from oxygen resulting in
the fuel that supports all eukaryotic life. However, it is a highly sensitive process and, unbal-
anced, leads to the generation of free radicals or ROS which have been linked as a mechanism
underlying many chronic human diseases including MC activation and inflammatory arthritis
[56,57]. ALM is a mitochondria- targeting fullerene derivative that has been previously shown
to home to mitochondria and inhibit inflammation [27,28]. ALM was designed to accumulate
in the internal mitochondrial membrane bilayers positioned to neutralize superoxide mole-
cules, reactive lipid radicals, and radicals that have formed on transmembrane proteins at the
site where they are generated. Subsequently, this is predicted to impact diseases whose patholo-
gies stem from radical injury.
To this end both fullerene derivatives significantly block ROS production and mitochondri-
al membrane potential. While it has been shown previously that human MC degranulation in
response to FcεRI and Fcγ-signaling involves ROS [58,59], it is not clear if blocking ROS di-
rectly blocks degranulation and cytokine production. Results here suggest that blocking ROS
using ALM and TGA in response to IC (an FcγRIIA-dependent stimuli [35]) parallels inhibi-
tion of mediator release. This is in line with previous work suggesting that fullerenes interfere
with the generation of mitochondrial-derived ROS [60–63]. It is also demonstrated that mito-
chondrial membrane potential is a critical determinant in human MC FcγR-mediated degranu-
lation. While further studies are needed these data suggest that fullerenes inhibit MC through a
mechanism involving the mitochondrial membrane potential and suggest a role of the mito-
chondria in human MC non-IgE mediator release.
Nuclear factor-kappa B is involved in the pathophysiology of inflammatory and efforts to
target its function through molecular targets in the pathway leading to its activation are under-
way [64–66]. This transcription factor induces both TNF-α and IL-1β gene expression which
can both in turn activate the NF-κB pathway inducing an autocrine loop which perpetuates in-
flammation. Interestingly, some of the drugs for RA were shown to block either the NF-κB acti-
vation cascade or its action [64,65,67]. For example, gold-containing therapeutics, TNF-α
inhibitors, and methotrexate, all regularly used for treating arthritis, can effect NF-κB function
[68–70]. Several fullerene derivatives, including ALM and TGA, inhibited IC-induced NF-κB
activation in human MC. Current studies are examining what signaling molecules in the ROS/
TNF/NF-κB pathway [49] are affected by fullerene derivatives.
Arthritic joint tissues demonstrate a striking predilection for uptake of ALM. Indeed, this
strong uptake may provide a partial basis for their efficacy in ameliorating K/BxN arthritis. It
was also demonstrated that fullerene derivatives inhibited the onset of arthritis in K/BxN
serum transfer arthritis in C57Bl/6 mice. There was a small but not significant improvement in
the CIA model. The K/BxN serum transfer model induces a rapid and severe synovitis depen-
dent on neutrophils, MC, and macrophages. A role for MC in this system had also been pro-
posed by studies in mice that lack MC on the basis of mutations affecting the Kit-KitL (stem
cell factor) axis (W/Wv,Sl/Sld, and Pretty2) [29,33]. These mice are resistant to disease
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induction following serum transfer, and susceptibility can be restored by MC engraftment.
However, studies in Kit-independent models of MC deficiency have not found an effect on ar-
thritis in this model, suggesting that the phenotype of Kit-mutant mice may reflect the role of
stem cell factor on lineages beyond the MC [50]. In the Cre-Master mice employed here, MC
deficiency results through a genotoxicity from high levels of Cre recombinase driven by the car-
boxypeptidase A3 locus, resulting in Trp53-dependent MC depletion. Whereas Cre-Master
still exhibit some residual arthritis inhibition by fullerenes, our data suggested that MC are not
the only relevant target of fullerenes in this system. Given the differences in MC phenotypes
and expression between the rodent and human systems [71], further studies are needed to de-
termine whether the effect of fullerenes on MC represents an interesting strategy for interven-
tion in human arthritis.
As in other studies using purified and well characterized fullerene derivatives [25,26,72–74],
no liver or kidney toxicity was detected using repeated dosing of concentrations higher than
that needed for in vivo efficacy. The in vivo imaging studies also demonstrated a lack of uptake
in other organs, which portends well for a favorable toxicity profile in clinical development of
ALM. More advanced toxicity studies would be needed to assess these two fullerene derivatives
before moving forward with human application.
In conclusion, it was demonstrated that not all fullerene derivatives exhibit the same ability
to inhibit inflammatory mediator release fromMC and synovial fibroblasts. Two fullerene de-
rivatives were able to significantly block the onset of serum-induced arthritis in vivo leading to
a blunted inflammatory response; however CIA-induced mice were refractory to fullerene
treatment. More studies are needed to identify those structure-activity relationships that are
dependent on the moieties added to the fullerene carbon cage in order to define the precise
mechanism by which these fullerene derivatives inhibit inflammatory disease.
Acknowledgments
We kindly thank Thorsten Feyerabend and Hans-Reimer Rodewald for the donation of the
Cpa3Cre mouse.
Author Contributions
Conceived and designed the experiments: CLK ALD PAN. Performed the experiments: CLK
ALD PAN PC DBB. Analyzed the data: CLK ALD PAN PC ALK DL. Contributed reagents/
materials/analysis tools: CLK ALD ZZ PAN PC. Wrote the paper: CLK ALD PAN.
References
1. Davies KJ. Oxidative stress: the paradox of aerobic life. BiochemSocSymp. 1995; 61: 1–31.
2. Park H, Bourla AB, Kastner DL, Colbert RA, Siegel RM. Lighting the fires within: the cell biology of auto-
inflammatory diseases. Nat Rev Immunol. 2012; 12: 570–580. doi: 510.1038/nri3261 PMID: 22828911
3. Arab HH, El-Sawalhi MM. Carvedilol alleviates adjuvant-induced arthritis and subcutaneous air pouch
edema: Modulation of oxidative stress and inflammatory mediators. Toxicol Appl Pharmacol. 2013; 27:
00040–00049.
4. Drafi F, Bauerova K, Kuncirova V, Ponist S, Mihalova D, Fedorova T, et al. Pharmacological influence on
processes of adjuvant arthritis: Effect of the combination of an antioxidant active substance with metho-
trexate. Interdiscip Toxicol. 2012; 5: 84–91. doi: 10.2478/v10102-10012-10015-10104 PMID: 23118593
5. ZhangW, Dai SM. Mechanisms involved in the therapeutic effects of Paeonia lactiflora Pallas in rheu-
matoid arthritis. Int Immunopharmacol. 2012; 14: 27–31. doi: 10.1016/j.intimp.2012.1006.1001 PMID:
22705050
6. Park MK, Jhun JY, Lee SY, Oh HJ, Park MJ, Byun JK, et al. Retinal attenuates inflammatory arthritis by
reciprocal regulation of IL-17-producing T cells and Foxp3(+) regulatory T cells and the inhibition of
osteoclastogenesis. Immunol Lett. 2012; 148: 59–68. doi: 10.1016/j.imlet.2012.05.008 PMID: 22841964
Fullerenes Inhibit Inflammatory Arthritis
PLOS ONE | DOI:10.1371/journal.pone.0126290 April 16, 2015 14 / 17
7. Lee EY, Lee CK, Lee KU, Park JY, Cho KJ, Byun JK, et al. Alpha-lipoic acid suppresses the develop-
ment of collagen-induced arthritis and protects against bone destruction in mice. Rheumatol Int. 2007;
27: 225–233. PMID: 16944157
8. Haqqi TM, Anthony DD, Gupta S, Ahmad N, Lee MS, Kumar GK, et al. Prevention of collagen-induced
arthritis in mice by a polyphenolic fraction from green tea. ProcNatlAcadSci. 1999; 96: 4524–4529.
9. Skoldstam L, Hagfors L, Johansson G. An experimental study of a Mediterranean diet intervention for
patients with rheumatoid arthritis. AnnRheumDis. 2003; 62: 208–214.
10. Jaswal S, Mehta HC, Sood AK, Kaur J. Antioxidant status in rheumatoid arthritis and role of antioxidant
therapy. ClinChimActa. 2003; 338: 123–129.
11. Nigrovic PA, Lee DM. Synovial mast cells: role in acute and chronic arthritis. ImmunolRev. 2007; 217:
19–37. PMID: 17498049
12. Castor W. The microscopic structure of normal human synovial tissue. Arthritis & Rheumatism. 2007;
3(2): 140–151.
13. Nigrovic PA, Lee DM. Mast cells in inflammatory arthritis. Arthritis ResTher. 2005; 7: 1–11.
14. Gruber B, Ballan D, Gorevic PD. IgE rheumatoid factors: quantification in synovial fluid and ability to in-
duce synovial mast cell histamine release. Clin Exp Immunol. 1988; 71: 289–294. PMID: 2450710
15. Gruber B, Poznansky M, Boss E, Partin J, Gorevic P, Kaplan AP, et al. Characterization and functional
studies of rheumatoid synovial mast cells. Activation by secretagogues, anti-IgE, and a histamine-re-
leasing lymphokine. Arthritis Rheum. 1986; 29: 944–955. PMID: 2427092
16. Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-
‡/cachectin. Nature. 1990; 346: 274–276. PMID: 2374592
17. Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T, et al. Synovial fibroblasts: key players in rheuma-
toid arthritis. Rheumatology(Oxford). 2006; 45: 669–675. PMID: 16567358
18. Noss EH, Brenner MB. The role and therapeutic implications of fibroblast-like synoviocytes in inflamma-
tion and cartilage erosion in rheumatoid arthritis. Immunol Rev. 2008; 223: 252–270. doi: 10.1111/j.
1600-065X.2008.00648.x PMID: 18613841
19. Choi Y, Arron JR, Townsend MJ. Promising bone-related therapeutic targets for rheumatoid arthritis.
Nat Rev Rheumatol. 2009; 5: 543–548. doi: 10.1038/nrrheum.2009.175 PMID: 19798028
20. Lean JM, Davies JT, Fuller K, Jagger CJ, Kirstein B, Partington GA, et al. A crucial role for thiol antioxi-
dants in estrogen-deficiency bone loss. J Clin Invest. 2003; 112: 915–923. PMID: 12975476
21. Garrett IR, Boyce BF, Oreffo RO, Bonewald L, Poser J, Mundy GR, et al. Oxygen-derived free radicals
stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest. 1990; 85: 632–
639. PMID: 2312718
22. Bai XC, Lu D, Liu AL, Zhang ZM, Li XM, Zou ZP, et al. Reactive oxygen species stimulates receptor ac-
tivator of NF-kappaB ligand expression in osteoblast. J Biol. 2005;Chem 280: 17497–17506. PMID:
15731115
23. Kamata H, Hirata H. Redox regulation of cellular signalling. Cell Signal. 1999; 11: 1–14. PMID:
10206339
24. Ryan JJ, Bateman HR, Stover A, Gomez G, Norton SK, Kepley CL. Fullerene nanomaterials inhibit the
allergic response. J Immunol. 2007; 179: 665–672. PMID: 17579089
25. Norton SK, Dellinger A, Zhou Z, Lenk R, Macfarland D, Kepley CL. A new class of humanmast cell and
peripheral blood basophil stabilizers that differentially control allergic mediator release. Clin Transl Sci.
2010; 3: 158–169. doi: 10.1111/j.1752-8062.2010.00212.x PMID: 20718816
26. Norton SK, Wijesinghe DS, Dellinger A, Sturgill J, Zhou Z, Kepley CL. Epoxyeicosatrienoic acids are in-
volved in the C(70) fullerene derivative-induced control of allergic asthma. J Allergy Clin Immunol.
2012; 130(3): 761–769. doi: 10.1016/j.jaci.2012.04.023 PMID: 22664166
27. Zhou Z, Lenk RP, Dellinger A, Wilson SR, Sadler R, Kepley CL. Liposomal formulation of amphiphilic ful-
lerene antioxidants. Bioconjug Chem. 2010; 21: 1656–1661. doi: 10.1021/bc1001664 PMID: 20839887
28. Dellinger A, Zhou Z, Lenk R, MacFarland D, Kepley CL. Fullerene nanomaterials inhibit phorbol myris-
tate acetate-induced inflammation. Exp Dermatol. 2009; 18: 1079–1081. doi: 10.1111/j.1600-0625.
2009.00904.x PMID: 19555428
29. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB, et al. Mast cells: a cellular link be-
tween autoantibodies and inflammatory arthritis. Science. 2002; 297: 1689–1692. PMID: 12215644
30. Pitman N, Asquith DL, Murphy G, Liew FY, McInnes IB. Collagen-induced arthritis is not impaired in
mast cell-deficient mice. Ann RheumDis. 2011; 70: 1170–1171. doi: 10.1136/ard.2010.134528 PMID:
21131642
Fullerenes Inhibit Inflammatory Arthritis
PLOS ONE | DOI:10.1371/journal.pone.0126290 April 16, 2015 15 / 17
31. Norton SK, Wijesinghe DS, Dellinger A, Sturgill J, Zhou Z, Kepely CL. Epoxyeicosatrienoic acids are in-
volved in the C(70) fullerene derivative-induced control of allergic asthma. J Allergy Clin Immunol.
2012; 130: 761–769 e762. doi: 10.1016/j.jaci.2012.04.023 PMID: 22664166
32. Malbec O, Daeron M. The mast cell IgG receptors and their roles in tissue inflammation. ImmunolRev.
2007; 217: 206–221. PMID: 17498061
33. Nigrovic PA, Binstadt BA, Monach PA, Johnsen A, Gurish M, Iwakura Y, et al. Mast cells contribute to
initiation of autoantibody-mediated arthritis via IL-1. ProcNatlAcadSci. 2007; 104: 2325–2330. PMID:
17277081
34. Irani AM, Bradford TR, Kepley CL, Schechter NM, Schwartz LB. Detection of MCT and MCTC types of
human mast cells by immunohistochemistry using newmonoclonal anti-tryptase and anti-chymase an-
tibodies. J Histochem Cytochem. 1989; 37: 1509–1515. PMID: 2674273
35. ZhaoW, Kepley CL, Morel PA, Okumoto LM, Fukuoka Y, Schwartz LB, et al. Fc gamma RIIa, not Fc
gamma RIIb, is constitutively and functionally expressed on skin-derived humanmast cells. J Immunol.
2006; 177: 694–701. PMID: 16785568
36. Kepley CL. Antigen-induced reduction in mast cell and basophil functional responses due to reduced
Syk protein levels. Int Arch Allergy Immunol. 2005; 138: 29–39. PMID: 16088210
37. Avnet S, Cenni E, Perut F, Granchi D, Brandi ML, Giunti A. Interferon-alpha inhibits in vitro osteoclast
differentiation and renal cell carcinoma-induced angiogenesis. IntJOncol. 2007; 30: 469–476.
38. Reers M, Smiley ST, Mottola-Hartshorn C, Chen A, Lin M, Chen LB, et al. Mitochondrial membrane po-
tential monitored by JC-1 dye. Methods Enzymol. 1995; 260:406–17.: 406–417. PMID: 8592463
39. Smiley ST, Reers M, Mottola-Hartshorn C, Lin M, Chen A, Smith TW, et al. Intracellular heterogeneity in
mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. ProcNa-
tlAcadSci. 1991; 88: 3671–3675. PMID: 2023917
40. Cossarizza A, Baccarani-Contri M, Kalashnikova G, Franceschi C. A newmethod for the cytofluori-
metric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation
5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochemical and Bio-
physical Research Communications. 1993; 197: 40–45. PMID: 8250945
41. Dellinger A, Zhou Z, Norton SK, Lenk R, Conrad D, Kepley CL, et al. Uptake and distribution of fullerenes
in humanmast cells. Nanomedicine. 2010; 6: 575–582. doi: 10.1016/j.nano.2010.01.008 PMID: 20138243
42. Wruck CJ, Fraqoulis A, Gurzynski A, Brandenburg LO, Kan YW, Chan K, et al. Role of oxidative stress
in rheumatoid arthritis: insights from the Nrf2-knockout mice. Ann Rheum Dis. 2011; 70: 844–850. doi:
10.1136/ard.2010.132720 PMID: 21173018
43. Holmdahl R, Bockermann R, Backlund J, Yamada H.The molecular pathogenesis of collagen-induced
arthritis in mice—a model for rheumatoid arthritis. Ageing ResRev. 2002; 1: 135–147. PMID: 12039453
44. Brand DD, Latham KA, Rosloniec EF. Collagen-induced arthritis. Nat Protoc. 2007; 2: 1269–1275.
PMID: 17546023
45. Nigrovic PA, Malbec O, Lu B, Markiewski MM, Kepley CL, Gerard N. C5a receptor enables participation
of mast cells in immune complex arthritis independently of Fcgamma receptor modulation. Arthritis
Rheum. 2010; 62: 3322–3333. doi: 10.1002/art.27659 PMID: 20662064
46. Dellinger AL, Brooks DB, Plunkett B, Vonakis BM, Sandros M, Zhou Z, et al. Effects of Novel Nanoma-
terials on Allergic Mediator Release from HumanMast Cells and Basophils through Non-Ige Mediated
Pathways. J Nanomed Nanotechol. 2012; 3: 8.
47. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial ROS-induced ROS release: an update and review.
Biochim Biophys Acta. 2006; 1757: 509–517. PMID: 16829228
48. Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res. 2011;
21: 103–115. doi: 10.1038/cr.2010.178 PMID: 21187859
49. Sun SC. The noncanonical NF-kappaB pathway. Immunol Rev. 2012; 246: 125–140. doi: 110.1111/j.
1600-1065X.2011.01088.x PMID: 22435551
50. Feyerabend TB, Weiser A, Tietz A, Stassen M, Harris N, Kopf M, et al. Cre-mediated cell ablation con-
tests mast cell contribution in models of antibody- and T cell-mediated autoimmunity. Immunity. 2011;
35: 832–844. doi: 10.1016/j.immuni.2011.09.015 PMID: 22101159
51. Schubert N, Dudeck J, Peng L, Karutz A, Speier S, Maurer M, et al. Mast cells promote T cell driven an-
tigen-induced arthritis despite being dispensable in T cell bypassing antibody-induced arthritis. Arthritis
& Rheumatology. 2014; 67: 903–913.
52. Steinitz K. A simple bedside test for renal function; the semiquantitative determination of blood creati-
nine. Harefuah. 1947; 32: 174. PMID: 20267150
53. Eklund KK. Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheu-
matic therapy. Immunol Rev. 2007; 217: 38–52. PMID: 17498050
Fullerenes Inhibit Inflammatory Arthritis
PLOS ONE | DOI:10.1371/journal.pone.0126290 April 16, 2015 16 / 17
54. Niedermeier M, Pap T, Korb A. Therapeutic opportunities in fibroblasts in inflammatory arthritis. Best
Pract Res Clin Rheumatol 2010; 24: 527–540. doi: 10.1016/j.berh.2010.02.002 PMID: 20732650
55. Solomon S, Kassahn D, Illges H. The role of the complement and the Fc gamma R system in the patho-
genesis of arthritis. Arthritis Res Ther. 2005; 7: 129–135. PMID: 15987494
56. Phillips DC, Dias HK, Kitas GD, Griffiths HR. Aberrant reactive oxygen and nitrogen species generation
in rheumatoid arthritis (RA): causes and consequences for immune function, cell survival, and therapeutic
intervention. Antioxid Redox Signal. 2010; 12: 743–785. doi: 10.1089/ars.2009.2607 PMID: 19686039
57. Winyard PG, Ryan B, Eggleton P, Nissim A, Taylor E, Lo Faro ML, et al. (2011) Measurement and
meaning of markers of reactive species of oxygen, nitrogen and sulfur in healthy human subjects and
patients with inflammatory joint disease. Biochem Soc Trans 39: 1226–1232. doi: 10.1042/
BST0391226 PMID: 21936794
58. Swindle EJ, Coleman JW, DeLeo FR, Metcalfe DD. FcepsilonRI- and Fcgamma receptor-mediated pro-
duction of reactive oxygen species by mast cells is lipoxygenase- and cyclooxygenase-dependent and
NADPH oxidase-independent. Journal of Immunology. 2007; 179: 7059–7071. PMID: 17982097
59. Swindle EJ, Metcalfe DD, Coleman JW. Rodent and humanmast cells produce functionally significant
intracellular reactive oxygen species but not nitric oxide. J BiolChem. 2004; 19: 48751–48759.
60. Foley S, Crowley C, Smaihi M, Bonfils C, Erlanger BF, Seta P, et al. Cellular localisation of a water-solu-
ble fullerene derivative. Biochemical and Biophysical Research Communications. 2002; 294: 116–119.
PMID: 12054749
61. Porter AE, Muller K, Skepper J, Midgley P, Welland M. Uptake of C60 by humanmonocyte macro-
phages, its localization and implications for toxicity: studied by high resolution electron microscopy and
electron tomography. Acta Biomater. 2006; 2: 409–419. PMID: 16765881
62. Chirico F, Fumelli C, Marconi A, Tinari A, Straface E, Malorni W, et al. Carboxyfullerenes localize within
mitochondria and prevent the UVB-induced intrinsic apoptotic pathway. ExpDermatol. 2007; 16: 429–
436. PMID: 17437486
63. Fumelli C, Marconi A, Salvioli S, Straface E, Malorni W, Offidani AM, et al. Carboxyfullerenes protect
human keratinocytes from ultraviolet-B-induced apoptosis. J Invest Dermatol. 2000; 115: 835–841.
PMID: 11069621
64. Roman-Blas JA, Jimenez SA. Targeting NF-kappaB: a promising molecular therapy in inflammatory ar-
thritis. Int Rev Immunol. 2008; 27: 351–374. doi: 10.1080/08830180802295740 PMID: 18853343
65. Bamborough P, Morse MA, Ray KP. Targeting IKKbeta for the treatment of rheumatoid arthritis. Drug
News Perspect. 2010; 23: 483–490. doi: 10.1358/dnp.2010.23.8.1447844 PMID: 21031164
66. Marcu KB, Otero M, Olivotto E, Borzi RM, Goldring MB. NF-kappaB signaling: multiple angles to target
OA. Curr Drug Targets. 2010; 11: 599–613. PMID: 20199390
67. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment
of inflammation and cancer. J Clin Invest. 2001; 107: 135–142. PMID: 11160126
68. Handel ML, Nguyen LQ, Lehmann TP. Inhibition of transcription factors by anti-inflammatory and anti-
rheumatic drugs: can variability in response be overcome? Clin Exp Pharmacol Physiol. 2000; 27: 139–
144. PMID: 10744338
69. Nam NH. Naturally occurring NF-kappaB inhibitors. Mini Rev Med Chem. 2006; 6: 945–951. PMID:
16918500
70. Majumdar S, Aggarwal BB. Methotrexate suppresses NF-kappaB activation through inhibition of Ikap-
paBalpha phosphorylation and degradation. J Immunol. 2001; 167: 2911–2920. PMID: 11509639
71. Schwartz LB, Huff TF. Biology of mast cells and basophils. Allergy: Principals and Practice. St. Louis:
Mosby-Year Book, Inc. 1993; 135–168.
72. Ehrich M, Van Tassell R, Li Y, Zhou Z, Kepley CL. Fullerene antioxidants decrease organophosphate-
induced acetylcholinesterase inhibition in vitro. Toxicol In Vitro. 2011; 25: 301–307. doi: 10.1016/j.tiv.
2010.09.010 PMID: 20888407
73. Dellinger A, Olson J, Zhou Z, Link K, Vance S, Kepley CL. Functionalization of gadoliniummetallofuller-
enes for detecting atherosclerotic plaque lesions by cardiovascular magnetic resonance. J Cardiovasc
Magn Reson. 2013; 15: 7. doi: 10.1186/1532-429X-15-7 PMID: 23324435
74. Adiseshaiah P, Dellinger A, Macfarland D, Stern S, Dobrovolskaia M, Kepley CL, et al. A Novel Gado-
linium-Based Trimetasphere Metallofullerene for Application as a Magnetic Resonance Imaging Con-
trast Agent. Invest Radiol. 2013; 45: 745–754.
Fullerenes Inhibit Inflammatory Arthritis
PLOS ONE | DOI:10.1371/journal.pone.0126290 April 16, 2015 17 / 17
